ColoSeq Tumor Panel
General Information
Lab Name
ColoSeq Tumor Panel
Lab Code
CSQTP
Epic Name
Order using "UW Genetics and Solid Tumor Test Request"
Place a separate order to draw the paired blood sample.
See tip sheet for more information (internal link).
Description
ColoSeq™ Paired Tumor-Germline Panel is designed to resolve unexplained mismatch repair deficiency by performing targeted tumor sequencing for somatic mismatch repair (MMR) mutations which have been reported in cancers with IHC loss of MMR protein(s) and normal (negative) germline MMR gene testing. ColoSeq™ Tumor Panel includes both a comprehensive pan-cancer germline analysis of 91 genes associated with hereditary cancer syndromes AND a targeted tumor assessment of select somatic and constitutionally mosaic somatic mutations to aid in the evaluation of mismatch repair deficiency. The tumor analysis includes microsatellite instability, detection of loss of heterozygosity and BRAF V600E mutation.
ColoSeq™ Tumor Panel resolves unexplained mismatch repair deficiency in more than 90% of patients who have mismatch repair deficient tumors and negative germline testing. All exons and flanking intronic sequences are analyzed for all panel genes. Complete promoter and intronic sequencing of the mismatch repair genes, as well as BRCA1/2, is performed, and non-coding variants of uncertain significance are assessed with RNA analysis when certain criteria are met. Select patients may be offered long range sequencing. Many patients undergoing paired tumor-germline testing have already undergone a lot of testing, and these assays are intended to provide conclusive results whenever possible.
ColoSeq™ Tumor assay is not intended to evaluate for somatic mutations for purposes of cancer treatment. Analysis for these tests is limited to select somatic and constitutional mosaic mutations to aid in the diagnosis of genetic and/or hereditary conditions and not all somatic mutations detected are reported.
ColoSeq™ Tumor Panel uses next-generation sequencing to detect most mutations in AKT1, ALK, APC, ATM, ATR, AXIN2, BAP1, BARD1, BMPR1A, BRAF, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDK12, CDKN1B, CDKN2A, CEBPA, CHEK2, CTNNA1, CTNNB1, DDX41, DICER1, EGFR, EPCAM, ETV6, FANCM, FH, FLCN, GATA2, GEN1, GREM1, HOXB13, KIF1B, KIT, LZTR1, MAX, MBD4, MEN1, MET, MITF, MLH1, MLH3, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NF2, NTHL1, PALB2, PDGFRA, PHOX2B, PIK3CA, PMS2, POLD1, POLE, POT1, PRKAR1A, PTCH1, PTEN, RAD51B, RAD51C, RAD51D, RB1, RECQL, RET, RINT1, RNF43, RPS20, RSPO3, RUNX1, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, SMARCE1, SUFU, STK11, TMEM127, TP53, TSC1, TSC2, VHL, and WT1.
Next-generation sequencing is performed on an Illumina instrument to detect single nucleotide variants, insertions, deletions, gene amplifications, and selected translocations.
NOTE: A germline sample is required if germline BROCA or ColoSeq ™ testing was not performed previously at the University of Washington. The germline sample is used to evaluate for the presence of the apparently somatic mutations detected in the tumor, including the identification of constitutional mosaicism. Approximately 7% of patients with prior negative germline testing are found to have a previously undetected pathogenic germline variant or constitutional mosaic mutation in one of the MMR genes.
For an overview of available germline and paired tumor-germline testing for hereditary cancer syndromes, please see: Hereditary Cancer Test Menu: Germline and Paired Tumor-Germline guideline.
ColoSeq Polyposis [CSQP] is available for the evaluation of unexplained polyposis.
ColoSeq Tumor Single Gene [CSQTS] is also available for the analysis of single gene(s) from the ColoSeq™ Tumor Panel.
ColoSeq™ Panel Genes
Gene |
Function/Pathway |
Heterozygote Cancer Risk* |
Associated disease/syndrome |
References |
ALK |
MYC signaling | Neuroblastoma |
Cowden-like |
18724359, 28674118 |
AKT1 |
AKT signaling | Breast, Thyroid |
Cowden-like |
23246288 |
APC |
WNT signaling | Colon |
Familial adenomatous polyposis |
20301519 |
ATM |
Double stranded break repair | Breast, Pancreatic |
Ataxia telangiectasia (recessive) |
16832357, 19781682, 22585167 |
ATR |
Double stranded break repair | Oropharyngeal |
Seckel (recessive) |
22341969 |
AXIN2 |
WNT signaling | Colon |
Colon cancer, oligodontia |
15042511 |
BAP1 |
BRCA1-associated protein complex | Uveal Melanoma, Mesothelioma |
BAP1 Tumor predisposition syndrome |
21874000, 21874003 |
BARD1 |
BRCA1-associated protein complex | Breast, Ovarian |
Hereditary breast cancer |
21344236 |
BMPR1A |
TGF-beta signaling | Colon |
Juvenile Polyposis |
20301642 |
BRAF |
Serine/Threonine protein kinase | Typically somatic or mosaic only |
Typically somatic only, association with MLH1 promoter hypermethylation in colon cancer and Cardiofaciocutaneous syndrome when mosaic |
20301365 |
BRCA1 |
BRCA1-associated protein complex | Breast, Ovarian |
Hereditary breast and ovarian cancer |
22006311,2270482,7545954 |
BRCA2 |
Fanconi/BRCA | Breast, Ovarian |
Hereditary breast and ovarian cancer, Fanconi anemia FA-D1 (recessive) |
22006311,8524414 |
BRIP1 |
Fanconi/BRCA | Breast, Ovarian |
Fanconi anemia FA-J (recessive) |
22006311,17033622,21964575 |
CDH1 |
Cell adhesion | Breast, Gastric |
Hereditary diffuse gastric cancer |
20301318 |
CDK4 |
Cell cycle | Melanoma |
Familial melanoma |
19585149 |
CDK12 |
MAP kinase regulation | Breast, Ovarian |
Typically somatic only; Hereditary breast and ovarian cancer |
24554720,29906450,24240700 |
CDKN1B |
Cyclin-dependent kinase inhibitor 1B | Parathyroid, Pituitary |
Multiple endocrine neoplasia, type IV |
37733893 |
CDKN2A |
Cell cycle | Pancreatic, Melanoma |
Familial melanoma and pancreatic cancer |
19585149 |
CEBPA |
Tumor suppressor | Leukemia |
Familial AML |
35178345 |
CHEK2 |
Double stranded break repair | Breast | Hereditary breast cancer | 11967536 |
CTNNA1 |
Beta-catenin, e-cadherin complex | Gastric |
Hereditary diffuse gastric cancer |
23208944 |
CTNNB1 |
WNT signaling | Typically somatic only |
Colon cancer, endometrial cancer, desmoid tumors, colon adenomas |
33115416, 37048063 |
DDX41 |
Splicing regulation | Leukemia, MDS |
Familial MDS, AML |
26712909,34723452 |
DICER1 |
Tumor suppressor | Wilms tumor, Pleuropulmonary blastoma |
DICER1 syndrome |
29343557,28960912,23625684 |
EGFR |
Epidermal growth factor receptor | Lung |
Familial lung cancer |
37274482 |
EPCAM |
Deletions inactivate MSH2, mismatch repair | Colon, Ovarian, Endometrial |
Lynch syndrome |
23938213 |
ETV6 |
Transcription factor in hemopoietic regulation | Leukemia, MDS |
Familial thrombocytopenia, MDS, acute leukemia |
28555414 |
FANCM |
Fanconi/BRCA | Breast |
Fanconi anemia (recessive) |
25288723 |
FH |
Tumor suppressor | Renal |
Hereditary leiomyomatosis and renal cell cancer |
25018647,11865300,25004247 |
FLCN |
Tumor suppressor | Renal |
Birt-Hogg-Dube syndrome. Primary spontaneous pneumothorax. |
12204536, 19659657 |
GATA2 |
Transcription factor in hemopoietic regulation | Leukemia, MDS |
Familial leukemia, MDS, immunodeficiency |
38660832, 36455197 |
GEN1 |
Double stranded break repair | Breast |
Hereditary breast cancer |
20512659 |
GREM1 |
BMP antagonist | Colon |
Hereditary mixed polyposis syndrome |
22561515 |
HOXB13 |
Sequence-specific transcription factor which binds preferentially to methylated DNA | Prostate |
Familial prostate cancer |
36446039, 34799695, 34059701 |
KIF1B |
Tumor suppressor | Neuroblastoma |
Hereditary neuroblastoma |
18334619, 24469107, 30859632 |
KIT |
Proto-oncogene which encodes a tyrosine-protein kinase that acts as a cell-surface receptor for cytokine KITLG/SCF | Gastrointestinal stromal tumors (GIST), Acute myelogenous leukemia (AML) |
Hereditary GIST and AML |
36351335, 35821557 |
LZTR1 |
RAS ubiquitination/MAPK signaling | Schwannomatosis |
Schwannomatosis, Noonan syndrome |
24362817, 25335490 |
MAX |
MYC signaling | Pheochromocytoma, Paraganglioma |
Hereditary pheochromocytoma and paraganglioma |
21685915, 22452945 |
MBD4 |
Mismatch DNA repair | Uveal Melanoma, myelodysplastic disease, colon polyposis |
Polyposis, multi-organ tumor predisposition (recessive) |
32239153, 35460607, 30049810 |
MEN1 |
Gene expression regulation | Endocrine |
Multiple endocrine neoplasia type 1 |
9215689 |
MET |
Tyrosine Kinase receptor | Kidney, Squamous cell carcinomas |
Hereditary papillary renal cell carcinoma |
11551094,9140397,27330189 |
MITF |
Melanocyte inducing transcription factor | Kidney, Melanoma |
MITF-related melanoma and renal cell carcinoma predisposition |
24290354,22012259 |
MLH1 |
Mismatch DNA repair | Colon, Ovarian, Endometrial |
Lynch syndrome |
20301390 |
MLH3 |
Mismatch DNA repair | Polyposis (recessive) |
unknown |
30573798 |
MSH2 |
Mismatch DNA repair | Colon, Ovarian, Endometrial |
Lynch syndrome |
20301390 |
MSH3 |
Mismatch DNA repair | Polyposis |
Familial adenomatous polyposis 4 (recessive) |
27476653, 35675019, 38243056 |
MSH6 |
Mismatch DNA repair | Colon, Endometrial |
Lynch syndrome |
20301390 |
MUTYH |
DNA repair | Colon |
MUTYH-associated polyposis (recessive) |
20301519, 21952991 |
NBN |
Double stranded break repair | Breast |
Nijmegen breakage syndrome (recessive) |
15185344,9590180 |
NF1 |
MAPK signaling | Optic Glioma, Peripheral Nerve Sheath, Breast |
Neurofibromatosis |
2114220, 23165953, 20301288 |
NF2 |
Cellular regulation | Acoustic neuromas, Vestibular Schwannomas |
Neurofibromatosis |
20301380 |
NTHL1 |
Base excision repair | Colon polyps, Endometrial, Breast, Pancreatic |
Hereditary cancer with colon polyposis (recessive) |
25938944, 26431160 |
PALB2 |
Fanconi/BRCA | Breast, Pancreatic |
Fanconi anemia FA-N (recessive) |
17200668,17200671,25099575 |
PDGFRA |
Protein tyrosine kinase | GIST, often somatic |
Familial, sporadic GIST |
25975287, 23036227 |
PHOX2B |
Tumor suppressor | Neuroblastoma |
Hereditary neuroblastoma |
17637745,28674118 |
PIK3CA |
AKT signaling | Breast, Thyroid |
Cowden-like |
22729224, 23246288 |
PMS2 |
Mismatch DNA repair | Colon, Endometrial |
Lynch syndrome |
20301390 |
POLD1 |
DNA Polymerase | Colon, Endometrial |
Familial polyposis, colorectal cancer |
23263490, 23770608 |
POLE |
DNA Polymerase | Colon |
Familial polyposis, colorectal cancer |
23263490 |
POT1 |
Telomere maintenance | Melanoma, CLL, Sarcoma, Glioma, Colon, Thyroid, Breast |
Multi-organ tumor predisposition |
23502782, 24686849, 28853721, 37140166 |
PRKAR1A |
cAMP signaling | Endocrine | Carney complex (recessive) | 4010501 |
PTCH1 |
Hedgehog | Basal cell carcinoma, PNET |
Nevoid basal cell-carcinoma syndrome |
8681379, 8658145, 20301330 |
PTEN |
PI3K/MAPK Signaling | Breast |
Cowden syndrome |
20301661 |
RAD51B |
Double stranded break repair | Unknown | Hereditary breast and ovarian cancer | 24139550 |
RAD51C |
Fanconi/BRCA | Ovarian, Breast | Hereditary breast and ovarian cancer | 22006311,22538716 |
RAD51D |
Fanconi/BRCA | Ovarian, Breast | Fanconi anemia FA-O (recessive) | 21822267,22415235 |
RB1 |
Tumor suppressor | Retinoblastoma, Sarcoma, Melanoma | Fanconi anemia (recessive) | 25621664,22355046,20301625 |
RECQL |
DNA repair | Breast | Hereditary retinoblastoma | 25915596 |
RET |
Receptor Tyrosine Kinase | Endocrine | Hereditary breast cancer | 20301434 |
RINT1 |
DNA checkpoint regulation | Breast, Colon | Multiple endocrine neoplasia type 2 | 25050558 |
RNF43 |
WNT signaling | Colon |
Sessile Serrated Polyposis |
27329244, 27081527 |
RPS20 |
Ribosomal protein | Colon |
unknown |
24941021 |
RSPO3 |
WNT signaling | Typically somatic only | Colon cancer | 29127379, 37048063 |
RUNX1 |
Hematopoietic stem cell regulation (transcription factor) | myelodysplastic syndrome and acute myeloid leukemia |
RUNX1-familial platelet disorder |
21148331 |
SDHA |
Succinate dehydrogenase complex | Pheochromocytoma, Paraganglioma |
Hereditary paraganglioma-pheochromocytoma |
20484225, 21752896 |
SDHAF2 |
Succinate dehydrogenase complex | Pheochromocytoma, Paraganglioma |
Hereditary paraganglioma-pheochromocytoma |
20301715 |
SDHB |
Succinate dehydrogenase complex | Pheochromocytoma, Paraganglioma |
Hereditary paraganglioma-pheochromocytoma |
11404820 |
SDHC |
Succinate dehydrogenase complex | Pheochromocytoma, Paraganglioma |
Hereditary paraganglioma-pheochromocytoma |
11062460 |
SDHD |
Succinate dehydrogenase complex | Pheochromocytoma, Paraganglioma |
Hereditary paraganglioma-pheochromocytoma |
10657297 |
SMAD4 |
TGF-beta signaling | Colon |
Juvenile Polyposis |
20301642 |
SMARCA4 |
SWI/SNF complex | Ovarian | Ovarian Hereditary small cell carcinoma of the ovary, hypercalcemic |
24658002 |
SMARCB1 |
ATP-dependent SWI/SNF chromatin remodeling complex | Schwannoma, Rhabdoid tumors, Meningioma | Schwannomatosis; Rhabdoid tumor predisposition syndrome type 1 | 28109176, 29706634 |
SMARCE1 |
DNA repair and replication | Spinal meningioma | Familial spinal meningioma | 23377182 |
STK11 |
Tumor suppressor | Breast, Colon, Pancreatic, Gastric, Hamartomas | Peutz-Jeghers syndrome | 20301443 |
SUFU |
Hedgehog Signaling | Basal cell carcinoma, Medulloblastoma, Meningioma, Gonadal tumors | Nevoid basal cell-carcinoma syndrome (Gorlin syndrome) | 19533801, 35768194 |
TMEM127 |
Tumor suppressor | Pheochromocytoma, Paraganglioma | Hereditary paraganglioma-pheochromocytoma | 20301715 |
TP53 |
Cell growth | Breast, Ovarian |
Li-Fraumeni syndrome |
22006311, 20301488 |
TSC1 |
Cell growth | Hamartomas |
Tuberous sclerosis complex |
10227394,9924605,17287951 |
TSC2 |
Cell growth | Hamartomas |
Tuberous sclerosis complex |
8825048,9829910 |
VHL |
p53 regulation | Kidney, Neuroendocrine |
von Hippel-Lindau syndrome |
20301636 |
WT1 |
WT1 transcription factor | Wilms tumor |
Wilms tumor |
15150775 |
For previous versions of ColoSeq™ - Lynch and Polyposis Panel, see Previous Versions, COSEQ.
References
- Pritchard CC, et al. ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing. J Mol Diagn 2012, 14:357-66. 22658618
- Walsh T, et al. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci U S A 2010, 107:12629-33. 20616022
- Nord AS, Lee M, King MC, and Walsh T. Accurate and exact CNV identification from targeted high-throughput sequence data. BMC Genomics 2011, 12:184. 21486468
- Metzker ML. Sequencing technologies - the next generation. Nat Rev Genet 2010, 11:31-46. 19997069
- Rhees J, Arnold M, and Boland CR. Inversion of exons 1-7 of the MSH2 gene is a frequent cause of unexplained Lynch syndrome in one local population. Fam Cancer 2014, 13:219-25. 24114314
- Mensenkamp AR, et al. Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndrome-like tumors. Gastroenterology 2014, 146:643-646.e8. 24333619
- Haraldsdottir S, et al. Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations. Gastroenterology 2014, 147:1308-1316.e1. 25194673
- Salipante SJ, Scroggins SM, Hampel HL, Turner EH, and Pritchard CC. Microsatellite instability detection by next generation sequencing. Clin Chem 2014, 60:1192-9. 24987110
Synonyms
AKT1, ALK, APC, ATM, ATR, AXIN2, BAP1, BARD1, biallelic somatic, BMPR1A, BRAF, BRCA1, BRCA2, BRIP1, CDH1, CDK12, CDK4, CDKN1B, CDKN2A, CEBPA, CHEK2, CTNNA1, CTNNB1, DDX41, DICER1, double somatic, EGFR, EPCAM, ETV6, FANCM, FH, FLCN, GATA2, GEN1, GREM1, HOXB13, KIF1B, KIT, Lynch syndrome, LZTR1, MAX, MBD4, MEN1, MET, mismatch repair deficiency, MITF, MLH1, MLH3, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NF2, NTHL1, PALB2, PDGFRA, PHOX2B, PIK3CA, PMS2, POLD1, POLE, POT1, PRKAR1A, PTCH1, PTEN, RAD51B, RAD51C, RAD51D, RB1, RECQL, RET, RINT1, RNF43, RPS20, RSPO3, RUNX1, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, SMARCE1, STK11, SUFU, TMEM127, TP53, TSC1, TSC2, VHL, WT1
Components
Code | Name |
---|---|
CTPGS | ColoSeq Tumor Gene Sequenced |
CTPRE | ColoSeq Tumor Result |
CTPIN | ColoSeq Tumor Interpretation |
CTPCH | ColoSeq Tumor Clinical History |
CTPMT | ColoSeq Tumor Methods |
CTPDI | ColoSeq Tumor Director |
Interpretation
Method
Next-generation sequencing.
This assay sequences all exons, flanking intronic splice site sequences, and select promoter regions of AKT1, ALK, APC, ATM, ATR, AXIN2, BAP1, BARD1, BMPR1A, BRAF, BRCA1*, BRCA2*, BRIP1, CDH1, CDK4, CDK12, CDKN1B, CDKN2A, CEBPA, CHEK2, CTNNA1, CTNNB1, DDX41, DICER1, EGFR, EPCAM, ETV6, FANCM, FH, FLCN, GATA2, GEN1, GREM1, HOXB13, KIF1B, KIT, LZTR1, MAX, MBD4, MEN1, MET, MITF, MLH1*, MLH3, MSH2*, MSH3, MSH6*, MUTYH, NBN, NF1, NF2, NTHL1, PALB2, PDGFRA, PHOX2B, PIK3CA, PMS2*, POLD1, POLE, POT1, PRKAR1A, PTCH1, PTEN, RAD51B, RAD51C, RAD51D, RB1, RECQL, RET, RNF43, RPS20, RSPO3, RUNX1, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, SMARCE1, SUFU, STK11, TMEM127, TP53, TSC1, TSC2, VHL, and WT1.
Gene introns are also sequenced for genes indicated above with an asterisk (*).
Sequences are aligned to the human genome reference (HG38). Test performed by targeted capture for listed genes followed by next-generation sequencing with Illumina technology. This test was developed and its performance characteristics determined by the University of Washington Department of Laboratory Medicine. It has not been cleared or approved by the US Food and Drug Administration. This laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical laboratory testing. This test is used for clinical purposes. It should not be regarded as investigational or for research.
Reference Range
See individual components
Ref. Range Notes
No mutations detected.
Guidelines
Ordering & Collection
Specimen Type
Collection
Tumor specimen will be requested directly, by UW Laboratory Medicine, from the originating pathology department. In order to facilitate this, a pathology report should be submitted with the test requisition, blood control and other clinical and billing paperwork.
NOTE: This test requires BOTH tumor tissue and peripheral blood. Only tumor tissue is required if ColoSeq™ testing on peripheral blood has been done previously at UW Lab Medicine.
Tumor Tissue:
Tumor specimen will be requested directly, by UW Laboratory Medicine, from the originating pathology department. In order to facilitate this, a pathology report should be submitted with the test requisition, blood control and other clinical and billing paperwork.
If the tumor specimen is being submitted by the ordering provider, tissue samples (FFPE) either (a) slides, OR (b) tissue block are required.
(a) Instructions for slide specimens: 1 slide at 4-micron thickness stained with hematoxylin-and-eosin AND 20 unstained, non-baked slides at 10-micron thickness (a minimum of 10 unstained slides is acceptable). Unstained slides can be on charged or uncharged slides. Note: Sections should contain as much tumor tissue as possible.
(b) Instructions for tissue block specimen: Provide complete tissue block containing tumor tissue. If there is more than one tissue block, please provide the block that has the greatest amount of tumor tissue. Tissue block will be returned at completion of testing. Ship at room temperature.
NOTE: If germline MMR testing was performed in a different laboratory, a peripheral blood sample should be submitted in addition to tumor tissue.
Germline control sample:
BLOOD:
- 10 mL whole blood in LAVENDER TOP EDTA tube.
- Also acceptable: YELLOW TOP ACD tube, purified DNA from peripheral blood or cultured cells.
SALIVA:
Contact laboratory for validated collection kit.
SKIN BIOPSY:
- Collection and transport: Obtain 2-4 mm punch biopsy of skin sample under sterile conditions and place in transport media (e.g. Alpha-MEM media, RPMI). Transport media can be supplied by the lab; call 206-598-4488 to request. If transport media is not available, the following media are acceptable alternatives if shipping time will not exceed 24 hours: lactated Ringer's solution, viral transport medium, or sterile saline. DO NOT USE formaldehyde, formalin, alcohol, or 5% dextrose, or tissue culture medium buffered with bicarbonate.
CULTURED CELLS:
- (2) T23 or (1) T75 flask (minimum 1-T25 flask).
Forms & Requisitions
Requisition Form and Ordering Instructions:
1. Fill out a Genetics Requisition Form
Providers with access to the UW implementation of Epic (i.e., FHCC, HMC, SCCA, UWMC, UWNW) may order this test using the order "UW Genetics and Solid Tumor Test Request." See tip sheet for more information (internal link).
2. Check "ColoSeq™ – Tumor Panel" or "ColoSeq™ - Tumor Single Gene" as desired.
3. For ColoSeq™ - Tumor Single Gene, specify gene in space provided.
4. Unless prior germline testing was performed at University of Washington, also select: "Normal Control (blood)."
5. Select the appropriate “Specimen Submitted."
6. Submit test requisition with peripheral blood sample and a copy of the tumor pathology report.
NOTE: Tumor specimen will be requested directly, by UW Laboratory Medicine and Pathology, from the originating pathology department, and therefore, in most cases, it is not necessary to submit tumor block or slides.
Handling Instructions
Attach a copy of the pathology report for the tumor sample being submitted.
Ship specimen at room temperature for overnight delivery.
Blood specimens can be held for up to 7 days before shipping if refrigerated.
Ship specimens to:
UW MEDICAL CENTER
LABORATORY MEDICINE - GENETICS LAB
1959 NE PACIFIC ST, ROOM NW220
SEATTLE, WA 98195-7110
Quantity
requested: Entire sample
minimum: Tissue: 10 unstained slides plus one H&E-stained; slide or extracted DNA: 5 microgram AND 5 mL control peripheral blood (DNAPRP)
Processing
Blood: Refrigerate whole blood
Unacceptable Conditions: Frozen or clotted specimens
Stability (collection to initiation of testing): Ambient: 5 days; Refrigerated: 7 days; Frozen: Unacceptable
Purified DNA: Refrigerate DNA specimens. Frozen is acceptable.
Performance
LIS Dept Code
Genetics (GEN)
Performing Location(s)
UW-MT |
Genetics
Attention: Genetics Lab Tel: 206-598–6429 M–F (7:30 AM–4:00 PM) Tel (EXOME only): 206-543-0459 |
Faculty |
---|
Frequency
Results within 4-6 weeks, once sample arrives in the laboratory.
Available STAT?
No
Billing & Coding
CPT codes
Billing Comments
For additional test/billing information, see following page, CPT codes for Hereditary Cancer Panels (germline and paired).
For pricing information, contact Client Support Services 206-520-4600 or 800-713-5198.
Billing and Insurance Pre-Authorization
We offer insurance pre-authorization services (preauthorization is only done for providers who are external to the UW system).
Email: gpab@uw.edu or call 1-855-320-4869 for more information.
A letter of medical necessity is highly recommended for ColoSeq™ Tumor testing, and a template is available by emailing genelab@uw.edu.
LOINC
Interfaced Order Code
UOW2961